NEW YORK (TheStreet) -- CHANGE IN RATINGS
Analog Devices was upgraded at Jefferies to buy. $56 price target. Company should continue to return the majority of its cash to shareholders in the coming years, Jefferies said.
Adtran was upgraded at Goldman Sachs to buy from neutral. $28 price target. Company should benefit from a multiyear upgrade cycle, Goldman said.
Advanced Micro was upgraded to buy from underperform at Bank of America/Merrill Lynch. $6 price target. Estimates were also increased, as the company is gaining market share with consoles.
Advanced Micro was upgraded at Canaccord Genuity to buy from hold. $5 price target. Ramp in the embedded business should continue to accelerate, Canaccord Genuity said.
On Assignment was downgraded at Deutsche Bank to hold from buy. Valuation call, based on a $29 price target, Deutsche Bank said.
Concur Technologies was initiated with a neutral rating at J.P. Morgan. Valuation call, based on an $80 price target, J.P. Morgan said.
China Cord Blood was upgraded to buy at TheStreet Ratings.
Community Health was initiated with a buy rating at Keybanc. $58 price target. Company has a solid track record and should receive above-average benefits from health care reform, Keybanc said.
Sourcefire was downgraded at UBS to neutral from buy based on valuation. Price target is $62.
Finisar was upgraded at Needham to strong buy from buy. $22 price target. Management meetings suggest that positioning and visibility are improving, Needham said.
Hess was upgraded at J.P. Morgan to overweight from neutral. $84 price target. Asset sale program can help unlock value, J.P. Morgan said.
Health Management was downgraded at Credit Suisse to neutral from outperform. Valuation call, based on a $16 price target, Credit Suisse said.
Jive Software was downgraded at UBS to neutral from buy. Valuation and sluggish demand for enterprise software, said UBS. Price target is $19.
KB Home was upgraded at CRT Capital to buy from hold. $23 price target. Earnings are coming in well ahead of expectations, CRT Capital said.
Lamar was upgraded at Citigroup to buy from neutral. The IRS is expected to rule in favor of the REIT transition, said Citigroup. Price target goes to $53.
Linear Technology was upgraded at Jefferies to buy. $44 price target. Company is leveraged to higher automotive and industrial growth, Jefferies said.
Optical Cable was downgraded to hold at TheStreet Ratings.
ON Semiconductor was downgraded at Jefferies to hold. $8.50 price target. Company may face multiple compression, as the chip sector is entering the late innings of the cycle, Jefferies said.
Palo Alto Networks was upgraded at UBS to buy from neutral. Unjustified low valuation despite industry leading growth, said UBS. Price target is $55.
Sprint Nextel was downgraded at Citigroup to neutral from buy. Margin expansion from Network Vision is priced in, said Citigroup. Price target is now $7.50.
Sprint Nextel was upgraded at Deutsche Bank to buy from hold. New analyst has an $8 price target. Company will be the king of new spectrum and can drive above-average growth over the next few years, Deutsche Bank said.
Tenet Healthcare was initiated with a hold rating at Keybanc. Valuation call, as the stock is up 115% over the past year, Keybanc said.
STOCK COMMENTS/EPS CHANGES
AmerisourceBergen numbers were boosted at Credit Suisse. Shares are now seen reaching $64. WAG deal should add to earnings, Credit Suisse said. Outperform rating.
Allergan price target was reduced at Lazard Capital Markets. Shares are now seen reaching $100. Restasis could face increased competition from generics, Lazard Capital Markets said. Buy rating.
Axiall numbers were cut at UBS. Earnings estimates were reduced on weak demand and operation issues, said UBS said. Price target is reduced to $44.
CBS price target was raised at Citigroup to $54. Reflects buyback enthusiasm, said Citigroup.
Family Dollar numbers were raised at Goldman Sachs. Shares are now seen reaching $69. Estimates were also increased, as the company is realizing better operating leverage, Goldman Sachs said. Neutral rating.
Mead Johnson Nutrition numbers were cut at Citigroup. Estimates were reduced given ongoing issues in Hong Kong, dairy inflation and China price pressures, said Citigroup. Price target goes to $77.
National Retail estimates were raised at UBS. Reflect the recent financing and increased acquisition estimates, said UBS. Price target is $33.50.
Occidental Petroleum price target was boosted at Citigroup to $93. A potential breakup should lead to limited upside in the stock, Citi said.
Synchronoss was added to the Best Ideas List at Wedbush. Pullback has created an attractive buying opportunity, Wedbush said. Outperform rating and $35 price target.
>To submit a news tip, email: firstname.lastname@example.org.
Follow TheStreet on Twitter and become a fan on Facebook.
EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he thinks could be potentially HUGE winners. Click here to see his holdings for FREE.
- Investment & Company Information
- Goldman Sachs
- Deutsche Bank